Skip to main content
Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: SAFit2 reduces neuroinflammation and ameliorates nerve injury-induced neuropathic pain

Fig. 4

SAFit2 treatment reduces NF-κB pathway activation in SNI-treated mice after 14 days. Mice underwent SNI surgery and were then treated with either vehicle or 10 mg/kg SAFit2 from day five to ten after the surgery. Lumbar L4–L6 DRGs and spinal cord were collected from ipsilateral and contralateral sides at day 14. A Representative Western blot of the total protein expression of the factors IKKβ, p65 and IκBα after vehicle and SAFit2 treatment. B–D Quantification of the total protein expression of IκBα (B), p65 (C) and IKKβ (D). E Representative Western blot of phosphorylated IκBα and p65 after vehicle and SAFit2 treatment. F, G Quantification of phosphorylated IκBα (F) and phosphorylated p65 (G) levels in DRGs and spinal cord. The data represent the mean ± SEM of 3–5 Western blots measured with the tissue pooled from 5 mice per group. *p < 0.05 Student´s t-test with Welch´s correction. SNI spared nerve injury, DRGs dorsal root ganglia, SC spinal cord, SAFit2 selective antagonist of FKBP51 by induced fit 2, IκBα NF-κB inhibitor alpha, IKKβ IκB kinase beta

Back to article page